Integrin-Blocking Polypeptides for Tumor Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for solid tumors and rheumatoid arthritis lack effective control over tumor proliferation, infiltration, and metastasis, as well as angiogenesis, which is a key factor in tumor growth and joint destruction in RA, with existing integrin blockers not being commercially available in China and having limitations in efficacy and side effects.
Innovation Solution
Development of two new integrin-blocking polypeptides, polypeptide II and polypeptide III, which incorporate an RGD sequence for high integrin affinity and an angiogenesis-inhibiting sequence, specifically targeting integrin αvβ3 to inhibit tumor growth, metastasis, and angiogenesis, thereby offering a broader therapeutic spectrum with reduced side effects and production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing integrin blockers are used, then some anti-tumor activity is achieved, but they are not commercially available in China and have limited efficacy and high side effects
Solution Approach 1:
The patent modifies the amino acid sequence parameters of integrin-blocking polypeptides by incorporating specific RGD sequences (Arg-Gly-Asp) at defined positions to enhance integrin affinity. The polypeptides are designed with specific lengths (40-60 amino acids) and contain optimized sequences that improve binding to integrin αvβ3 while reducing off-target effects, thereby enhancing efficacy and reducing side effects.
Solution Approach 2:
The invention creates composite polypeptide structures that combine multiple functional sequences: the RGD ligand sequence for integrin binding, the angiogenesis-inhibiting sequence (Phe-Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Ala-Arg-Ala-Val-Gly-Leu-Ala-Gly-Thr-Phe-Arg-Ala), and optional terminal sequences. This composite design achieves synergistic effects that improve therapeutic outcome while managing toxicity.
2Reliability
If polypeptides with RGD sequence are designed to target integrin αvβ3, then tumor-targeting performance and integrin affinity are improved, but the complexity of polypeptide design and production increases
Solution Approach 1:
The polypeptide is segmented into distinct functional modules: an N-terminal RGD sequence (Arg-Gly-Asp) for integrin binding, a central angiogenesis-inhibiting sequence (40-50 amino acids), and optional C-terminal sequences. This segmentation allows independent optimization of each function while simplifying the overall design process and facilitating production through standardized synthesis protocols.
Solution Approach 2:
The polypeptide design incorporates universal features that can be applied across different tumor types and conditions. The RGD sequence provides universal integrin binding capability, while the angiogenesis-inhibiting sequence serves multiple functions: blocking tumor angiogenesis, inhibiting metastasis, and potentially inducing apoptosis. This multi-functionality reduces the need for multiple different polypeptide designs.
3Reliability
If the angiogenesis-inhibiting sequence is optimized for tumor growth inhibition, then anti-tumor performance is enhanced, but the production cost and time required increase
Solution Approach 1:
The patent optimizes the sequence parameters of the angiogenesis-inhibiting region by selecting specific amino acid residues that have been shown to be critical for activity. The sequence length is controlled within 40-60 amino acids to balance activity with synthesizability. Key positions such as the RGD motif and conserved residues in the angiogenesis-inhibiting sequence are maintained while allowing variability in other regions to reduce production costs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides demonstrate strong tumor-targeting performance, high integrin affinity, and effective inhibition of angiogenesis, showing promising therapeutic effects on various tumors and RA, with potential for wide-ranging indications and improved patient outcomes.
Implementation Method 1
Integrin αvβ3 can recognize the sequence Arg-Gly-Asp (RGD) in its ligands, which means that an RGD-containing polypeptide can function as an integrin antagonist
Implementation Method 2
These features provide integrin-targeting polypeptides very promising prospects in tumor treatment. Integrin-targeting polypeptides can block intracellular signaling pathways downstream of the integrin and effectively inhibit tumor growth and metastasis by means of slowing down angiogenesis.
Data Source
AI summary
A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas.